A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combinedwith primaquine for radical treatment of vivax malaria in sumatera, Indonesia

Journal of Infectious Diseases

Volumn 208, Issue 11, 2013, Pages 1906-1913

  Pasaribu, Ayodhia Pitaloka ^a,b   Chokejindachai, Watcharee ^a   Sirivichayakul, Chukiat ^a   Tanomsing, Naowarat ^a   Chavez, Irwin ^a   Tjitra, Emiliana ^c   Pasaribu, Syahril ^b   Imwong, Mallika ^a   White, Nicholas J ^a,d   Dondorp, Arjen M ^a,d  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF SUMATERA UTARA   (Indonesia)

^c NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT   (Indonesia)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Indonesia; Plasmodium vivax; Primaquine; Radical cure

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ANTIHISTAMINIC AGENT; ARSUAMOON; ARTERAKINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; DOXYCYCLINE; PRIMAQUINE; QUININE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HUMAN; INDONESIA; INTRAVASCULAR HEMOLYSIS; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PARASITOLOGY; PERICARDITIS; PLASMODIUM VIVAX MALARIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT DISEASE; REINFECTION; SCHOOL CHILD; SIDE EFFECT; TREATMENT OUTCOME; URINE COLOR; URTICARIA;

INDONESIA; PLASMODIUM VIVAX; PRIMAQUINE; RADICAL CURE;

ADOLESCENT; ADULT; AGED; AMODIAQUINE; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; INDONESIA; KAPLAN-MEIER ESTIMATE; MALARIA, VIVAX; MALE; MIDDLE AGED; PLASMODIUM VIVAX; PRIMAQUINE; PROSPECTIVE STUDIES; QUINOLINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84888598835     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit407     Document Type: Article

References (24)

1. Guerra CA, Snow RW, Hay SI. Mapping the global extent of malaria in 2005. Trends Parasitol 2006; 22:353-8.
2. Baird JK, Schwartz E, Hoffman SL. Prevention and treatment of vivax malaria. Curr Infect Dis Rep 2007; 9:39-46.
3. World Health Organization. Guidelines for the treatment of malaria. 2nd ed. Geneva, Switzerland: WHO, 2010.
4. Alving AS, Arnold J, Hockwald RS, et al. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med 1955; 46:301-6.
5. Matsuoka H, Ishii A, Panjaitan W, Sudiranto R. Malaria and glucose- 6-phosphate dehydrogenase deficiency in North Sumatra, Indonesia. Southeast Asian J Trop Med Public Health 1986; 17:530-6.
6. Sutanto I, Endawati D, Ling LH, Laihad F, Setiabudy R, Baird JK. Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia. Malar J 2010; 9:52.
7. Baird JK, Sustriayu Nalim MF, Basri H, et al. Survey of resistance to chloroquine by Plasmodium vivax in Indonesia. Trans R Soc Trop Med Hyg 1996; 90:409-11.
8. Sumawinata IW, Bernadeta A, Leksana B, et al. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg 2003; 68:416-20.
9. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 2010; 10: 405-16.
10. DitJen PPL, Kes RI. Gebrak Malaria: Pedoman Penatalaksanaan Kasus Malaria di Indonesia. Jakarta, Indonesia: Ministry of Health, 2008.
11. Nuchprayoon I, Sanpavat S, Nuchprayoon S. Glucose-6-phosphate dehydrogenase (G6PD) mutations in Thailand: G6PD Viangchan (871G>A) is the most common deficiency variant in the Thai population. Hum Mutat 2002; 19:185.
12. World Health Organization. Malaria assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva, Switzerland: WHO, 2003.
13. Buchachart K, Krudsood S, Singhasivanon P, et al. Southeast Asian J Trop Med Public Health 2001; 32:720-6.
14. Moiz B, Nasir A, Moatter T, Naqvi ZA, Khurshid M. Population study of 1311 C/T polymorphism of glucose 6 phosphate dehydrogenase gene in Pakistan-an analysis of 715 X-chromosomes. BMC Genet 2009; 10:41.
15. Beutler E, Kuhl W. The NT 1311 polymorphism of G6PD: G6PD Mediterranean mutation may have originated independently in Europe and Asia. Am J Hum Genet 1990; 47:1008-12.
16. Louicharoen C, Patin E, Paul R, et al. Positively selected G6PD Mahidol mutation reduces Plasmodium vivax density in Southeast Asians. Science 2009; 326:1546-9.
17. Guindo A, Fairhurst RM, Doumbo OK, Wellems TE, Diallo DA. X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria. PLoS Med 2007; 4:e66.
18. Powell RD, Brewer GJ. Glucose-6-phosphate dehydrogenase deficiency and falciparum malaria. Am J Trop Med Hyg 1965; 14: 358-62.
19. Imwong M, Snounou G, Pukrittayakamee S, et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis 2007; 195:927-33.
20. Sutanto I, Tjahjono B, Basri H, et al. Randomized, open label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrob Agents Chemother 2013; 57:1128-35.
21. Navaratnam V, Ramanathan S, Wahab MS, et al. Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers. Eur J Clin Pharmacol 2009; 65:809-21.
22. Tarning J, Lindegardh N, Annerberg A, et al. Pitfalls in estimating piperaquine elimination. Antimicrob Agents Chemother 2005; 49: 5127-8.
23. Hasugian AR, Purba HL, Kenangalem E, et al. Dihydroartemisininpiperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis 2007; 44: 1067-74.
24. Smithuis F, Kyaw MK, Phe O, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: An open-label randomised trial. Lancet Infect Dis 2010; 10:673-81.